Osteoblast biology study ( DrugBank: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 238 | Vitamin D-resistant rickets | 1 |
238. Vitamin D-resistant rickets
Clinical trials : 29 / Drugs : 25 - (DrugBank : 11) / Drug target genes : 4 - Drug target pathways : 20
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04159675 (ClinicalTrials.gov) | October 1, 2020 | 7/11/2019 | Burosumab and 1-25 (OH) Vitamin D on Human Osteoblasts | Effect of Burosumab and 1-25 (OH) Vitamin D on Human Osteoblasts From Patients Requiring Craniosynostosis Surgery for Idiopathic Reason or Due to Hypophosphatemic Rickets (HR) | Craniosynostoses | Biological: osteoblast biology study | Hospices Civils de Lyon | NULL | Not yet recruiting | 4 Months | 18 Years | All | 20 | France |